FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 590 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 27-Year-Old Fighting Stage IV Cancer Gets Hit By COVID-19 And Sepsis... May 29, 2020 First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... July 5, 2021 Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 6 things you need to know about cervical screening October 25, 2021 Load more HOT NEWS 10 Things Diet Soda Does to Your Body If You Drink... FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable...
